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were showing significant MAPCAs. There was statistical signifi-
cant association between hypoplastic LPA &RPA and presence of
MAPCAs (p-value <0.0001). 21 (75%) patients out of 56 with pres-
ence of MAPCAs, had O2 saturation of >80%, while only 6 (22.2%)
had O2 saturation <70%. 21 (77.8) Oxygen saturation had statisti-
cal significant association with MAPCAs present (pvalue¼0.0062).
Out of 56 patients with MAPCAs present, 34 (60.7%) were greater
than 5 years of age. Greater than 5 years age group of patients had
statistical significant association with the presence of MAPCAs (p
value¼0.038). Patients with hypoplastic pulmonary artery
branches hadmore number of MAPCAs with direct origin. (p value
<0.001). The diameter of MAPCAs  3 mm was present in 19
(70.3%) and 26 (65%) patients with hypoplastic LPA and hypo-
plastic RPA respectively.
Conclusions: MAPCAS were present in significant no. of patients
of TOF/PA/severe PS and were significantly associated with hy-
poplastic pulmonary arteries, higher O2 saturation, and higher
age. Also size of MAPCAS was inversely related to the size of
pulmonary arteries.
Right ventricular form and functional assessment
after percutaneous atrial septal defect device
closure
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Objectives: We sought to assess the right heart’s response to
percutaneous device closure of moderate sized atrial septal de-
fects (ASDs) in adults over a one-year follow-up period. We also
study the right ventricular function (RV) assessed by myocardial
performance index (MPI).
Background: Percutaneous ASD device closure is a safe and
effective means of reducing or eliminating interatrial shunting.
The response of the adult’s right heart to device closure is
incompletely understood.
Methods: 25 adult patients underwent secundum ASD device
closure from December 2012 to July2013 at tertiary care center in
Mumbai. Of which 23 had Amplatzer device occluder and 2 life-
tech device). The patients were assessed with echocardiography,
chest radiography and electrocardiography before the procedure
and at 1, 6 and 12 months.Data are presented as the mean value
±SD fornormally distributed data obtained before the procedure
and at 1, 6 and 12 months after the procedure. Echocardiographic,
ECG and chest radiographic variables at each follow-up period
were compared with the pre-procedural values.
Results: The mean ASD size was 21± 5.80 mm, and the device size
ranged from 14mm to 36 mm. At one month, heart size (49% vs.
45%),four-chamber right ventricular (RV) size (45 vs. 40 mm),
paradoxical septal motion (80% vs.8%), QRS duration (110 vs. 104
ms), PR interval (178 vs. 157ms) and echocardiographically deter-
mined significant improvement in RV MPI (0.36 to 0.28, p  0.004),
pulmonary artery systolic pressure decreased significantly and
was maintained at12-month follow-up. At six months, right atrial
length decreased from 48 to 41 mm. At one year, 20% of patients
had persistent RV enlargement.
Conclusions: Right heart morphology undergoes rapid improve-
ment within one month of defect closure, with associated
mechanoelectrical benefit. Device closure of ASDs leads to
improvement of RV function too. A small number of patients had
persistent RV enlargement or pulmonary hypertension, or both, at
one year. Our data support the application of transcatheter
methods in achieving excellent hemodynamic and anatomic
outcomes.
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Background: Patients with congenital heart disease with PAH are
frequently subjected to preoperative cardiac catheterization for
determining operability based on various hemodynamic param-
eters as also the PVR,PVRI and shunt fractions.This study was
conducted to determine whether, during a cath study for deter-
mination of operability in shunt lesions,an improvement in pul-
monary saturation alone, a fall in pulmonary artery mean or
diastolic pressure or a combination of the two was better in
prognosticating postoperative outcomes especially post operative
PAH.
Methods: 50 (M¼22, F¼28) patients who had shunt lesions and
PAHwere serially recruited between Jan 1 2012 to Jan 1 2013 for the
study. Of these, 32 patients had been given at least a three month
course of sildenafil and then underwent cath. All 50 patients un-
derwent a preoperative cath study which consisted of measure-
ment of pulmonary artery systolic and end-diastolic pressures,
pulmonary and systemic saturation, pulmonary wedge pressures,
as well as systemic saturation, and measurement of the same
parameters after administration of 100% oxygen for 10 minutes.
Suitable sized wedge catheters were employed for this purpose.
PVR, PVRI, SVR, SVRI and shunt fraction Qp:Qs were calculated by
the usual formulae.The patients were then followed up immedi-
ately postoperatively during hospital stay and at third- month
follow-up visit ( non invasively).
Results: Average age of the patients was 12.8+/-1.28 years. Of the
50 patients who underwent cath, (ASD¼14 VSD ¼23, PDA¼7, APW
¼3, TAPVC¼2, Lutembacher¼1), post operative need for longer ICU
stay and ventilation, and need for milrinone was seen in 13 pa-
tients. Multiple regression analysis and Pearsons rank linear cor-
relation coeefficients were calculated for each of the
hemodynamic parameters in correlation with the use of milri-
none for post op PAH and for residual PAH at third month fol-
lowup. This had good relation with degree in fall in PA end
diastolic pressure (r¼0.67 for fall in PA diastolic pressure ) .Fair
corelation was seen for improvement in pulmonary artery satu-
rations during oxygen administration in pre op cath( r¼ 0.61)and
fall in PA systolic pressure with oxygen¼0.61)and with PA mean
pressure drop with oxygen administration(r¼0.60 ).However the
strongest correlation was seen with combination of both fall in
PAEDP and improvement in pulmonary artery saturations(0.74
when combination of fall in PA diastolic pressure and improve-
ment in PA sats), indicating best outcomes when both these pa-
rameters were satisfied.
Conclusion: The PRECIOUS-CHD inferred that a combination of
both fall in PAEDP and improvement in pulmonary artery saturation
with oxygen administration during preoperative cath may be a
better predictor of post operative outcomes after surgery for
congenital heart disease than a fall in the PA mean or a fall in PVR
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alone or improvement in PA saturations alone. Likewise a fall in
PAEDP and poor improvement in saturations leads to higher post-
operative residual PAH and longer ICU ventilator need and need
for milrinone to counter postoperative residual PAH.
Comparison of ambrisentan with sildenafil in
congenital heart disease with irreversible
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P.M. Raut, S. Prabhu, N.S. Waghmare, S. Shivpuje, N.O. Bansal
Sir J.J.Group of hospitals, Mumbai, India
Background: The pathogenesis of PAH involves endothelial
dysfunction characterised by over-expression of vasoconstrictors
such as endothelin-1 (ET-1) and thromboxane A2. Endothelin re-
ceptor antagonists (ERAs) are a class of potent vasodilators and
antimitotic substances. Aims&Objectives - To assess the efficacy of
endothelin receptor antagonists (ERAs) Ambrisentanin the treat-
ment of patients with PAH secondary to congenital heart disease.
Methods: It is a retrospective observational study, carried out at
single tertiary care center. Patient of acyanotic congenital heart
diseases (e.g.VSD, PDA, AV canal defect) admitted in cardiology
department, found to have irreversible pulmonary hypertension
on cardiac catheterization were enrolled in study. A total of 42
patients were enrolled in the study, 24 patients had received 10
mg of ambrisentan and remaining group 20 patient had received
sildenafil at maximum tolerated dose for at least 6 months.
Primary outcomes were exercise capacity (a six-minute walk
test (6MWD)) and World Health Organization (WHO) functional
class or New York Heart Association (NYHA) functional class.
Secondary outcome- Adverse events (for example, hepatic
toxicity).
Results: An increase in the 6MWD was reported in the ambri-
sentan group . Increases in the 6MWDat 24weekswas 51meters in
Ambrisentan group compared to 20 meters in sildenafil
group.(95% CI 27e76; P , 0.001). Patient enrolled in the study were
prominently WHO functional classification II (29%) and III (65%).
Study demonstrated a significant improvement in WHO func-
tional classification for patients receiving ambrisentan as
compared with sildenafil (P ¼ 0.036). Of the patients receiving
ambrisentan, 2 (9.7%) discontinued because of adverse events (
gastroenteritis,headache/face edema [n¼1 for each].Side effect of
ambrisentanwas found to be headache 2 (9.0%), peripheral edema
4(18.18%).No evidence of hepatotoxicity like elevated liver en-
zymes, bilirubin in ambrisentan group.
Conclusion: Study demonstrate the efficacy and safety of ambri-
sentan in the treatment of patients with symptomatic PAH. The
favorable efficacy-to-safety profile of ambrisentan may offer po-
tential advantages over the currently approved treatment options.
Our experience of percutaneous ventricular septal
device closure at our centre (tertiary care) e
Retrospective study
Rameshwar Sanap, Sandesh Prabhu, Sanjay Shivpuje, N.O. Bansal
JJ hospital, Mumbai, India
Background: Ventricular septal defect (VSD) is the most common
congenital heart defect at birth, as well as one of the common
heart defects in adult age group. Repair of ventricular septal defect
(VSD) has been historically performed surgically. However,
percutaneous VSD closure is also feasible and the frequency has
increased given the desire of young patients to avoid surgery.
Standard treatment of VSD is open surgery, which is widely per-
formed with but still carries risks, such as complete atrioven-
tricularblock , residual shunt, postpericardiotomy syndrome, and
wound infection. Transcatheter VSD device closure is a treatment
option for isolated uncomplicated muscular VSDs, and for mem-
branous VSDs, in selected patients with suitable anatomy.
Appropriate anatomy for transcatheter closure includes a VSD
location remote from the tricuspid and aortic valves with an
adequate rim of tissue.
Here we are presenting our experience about percutaneous VSD
device closure or attempted VSD device closure in 12 patients at
tertiary care centre.
Methods: Between June 2013 and July 2014 patients undergoing
percutaneousVSD device closure or attempted VSD device closure
were studied retrospectively. All patients underwent detailed
conventional two dimensional and colour Doppler transthoracic
echocardiography to study the type of VSD, shunt across the VSD ,
length of aortic rim and pulmonary hypertension.VSD size was
confirmed angiographically and device closure was done under
general anesthesia with TEE guidance according to standard
protocol. During immediate postoperative period, rhythm and
position was monitored by doing ECG and TTE respectively. Pa-
tients were given weight based aspirin and clopidogrel for 6
months. Patients were followed up on outpatient basis every 6
months for 1 yr and then every year and TTE was done during
each visit.
Result: There were total 12 patients out of which successful device
closure was done in 10 patients. The average age of patient was 6.9
yrs (ranges 2.5 to 18 yrs). The 5(41.6%) patients were female and 7
(58.3%) weremale. Themedian size of VSDwas 5.3mm (ranges 2.3
to 16 mm) one (8.3%) patient had two VSD. Average size of device
used was 7.1 mm .procedure related complication occurred in 4
patients. One (8.3%) patient had CHB after releasing of LV disc
hence procedure was abandoned. One (8.3%) patient had embo-
lization of device in the aorta which was successfully retrieved by
transcutaneous route. No patient had postprocedure death.No
Patients had postoperative rhythm disturbances. All patients
were discharged two days after procedure. All patients were
follow up at six month and 1 year by ECG and transthoracic
echocardiography.
Conclusion: In experienced hands, transcatheter VSD closure can
be performed safely and successfully with low morbidity and-
mortality. Transcatheter approach provides a less-invasive alter-
native that may become the first choice in selected VSD patients.
Experience with large ostium secundum atrial
septal defect (ASD) closure by transcatheter
percutaneous device (device) at J.J.Hospital
D.K. Ware, N.O. Bansal, S. Prabhu, S. Shivapuje
GMC and J.J. Hospital, Mumbai, India
Background: Small ASD are routinely closed by device.Larger ASD
by device closure is problematic. But, in these defects also, device
closure has high success. We present our experience of device
closure of ASD measuring >25 mm.
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